Pharmacological ULK1 activation with LYN-1604 restores sunitinib sensitivity in PDZK1-knockdown cells and synergizes with sunitinib in xenograft models, reducing tumor growth and LD accumulation. The gene discussed is ULK1; the disease is neoplasm.